| Literature DB >> 36230282 |
Sepideh Fallahi1, Łukasz Bobak2, Sebastian Opaliński1.
Abstract
In recent years, interest in hemp use has grown owing to its chemical and medicinal properties. Several parts of this plant, such as seeds, leaves, flowers, and stems are used in medicine, industry, and environmental preservation. Although there were legal restrictions on hemp exploitation in some countries due to the trace presence of THC as a psychoactive element, many countries have legalized it in recent years. Cannabidiol or CBD is a non-psychoactive phytocannabinoid that can activate the endocannabinoid system and its receptors in the central and peripheral nervous system in bodies of different species. Cannabidiol has anti-inflammatory, antioxidative, analgesic, and anti-depressant effects. This review investigates various aspects of cannabidiol use and its potential in animals and humans.Entities:
Keywords: CBD; Cannabis sativa; feed; livestock; poultry
Year: 2022 PMID: 36230282 PMCID: PMC9559627 DOI: 10.3390/ani12192541
Source DB: PubMed Journal: Animals (Basel) ISSN: 2076-2615 Impact factor: 3.231
Different varieties of Cannabis [1].
| Species | Varieties | |
|---|---|---|
| Domesticated | Wild | |
|
|
|
|
|
|
|
|
Figure 1Molecular structure of cannabidiol (CBD).
Figure 2Biosynthesis of CBD.
Figure 3Stages of cannabinoid extraction.
Different parts of the endocannabinoid system.
| Main units | Description | Functions | Compounds |
|---|---|---|---|
| Endocannabinoids | Lipid compounds metabolized in multiple enzymatic pathways | Binds to the receptors, | Neurotransmitters: anandamide-N-arachidonylethanolamine (AEA) and 2-arachidonylglycerol (2-AG) |
| Cannabinoid receptors | Able to stimulate receptors, produces physiological responses | G protein-coupled receptors (GPCRs), also known as 7-transmembrane receptors (7-TM receptors) and their endogenous ligands [ | |
| CB1 receptors | Found in the central nervous system, e.g., brain and spinal cord, some cells in the immune system, muscles, liver, kidney, lungs, reproductive system, and adipose tissues | Mediates the release of neurotransmitters: acetylcholine, noradrenaline, dopamine, gamma-aminobutyric acid (GABA), and glutamate | |
| CB2 receptors | Active receptors in the peripheral nervous system, e.g., immune system, liver, kidney, adipose tissues, and spleen | Releases cytokines, | |
| Enzymes | Involved in synthesis and catabolism [ | Fatty acid amide hydrolase (FAAH), monoacylglycerol lipase |
Anti-nociceptive and anti-inflammatory effects of CBD in different species.
| Species | Type of Pain or Disorder | CBD Amount and Duration | Results | Reference |
|---|---|---|---|---|
| Dogs (16) | OA a pain and lameness | CBD oil b 2 mg/kg every 12 h, 4 weeks | Significant reduction in pain, no significant difference in lameness degree | [ |
| Dogs (37) | Chronic maladaptive | CBD oil c | Significant reduction in pain, increase in mobility and quality of life | [ |
| Dogs (20) | OA pain | 20 mg/day (0.5 mg/kg) | Significant reduction in pain, increase in mobility | [ |
| Rats | RA f pain | CBD gels g (0.6, 3.1, 6.2 or 62.3 mg/day) for 4 days after arthritis | Significant decrease in joint swelling, inflammation biomarkers, pain scores, and synovial membrane thickness | [ |
| Rats | Spared nerve injury | Repeated CBD injections h (0.1–1.0 mg/kg) | Declined mechanical allodynia, anxiety-like behavior | [ |
| Rats | Exposed to pain (paw pressure and tail-flick test) | Intra-ventrolateral periaqueductul grey (PAG) microinjections of CBD (1.5, 3 and 6 nmol) | Reduction in activity of ON and OFF neurons, anti-nociceptive responses in the tail-flick test | [ |
| Mice | Sciatic nerve injury (neuropathic pain i) | CBD-containing gelatine j, orally ad libitum | Significant reduction in pain after 3 weeks of surgery | [ |
| Mice | Type 1 diabetes | 5 mg/kg CBD k, 5 times weekly for 10 weeks | Significant reduction in leukocyte activation, increase in pancreatic microcirculation | [ |
| Mice | Spinal cord injury | Intraperitoneal injections of CBD l 1.5 mg/kg, for 10 weeks following injury | Reduction in pro-inflammatory cytokine, prevented thermal sensitivity development | [ |
| Human | Peripheral neuropathic pain | Transdermal CBD (250 mg CBD/3 fl. Oz) | Significant reduction in severe pain, cold and itchy sensations | [ |
| Human | Treatment-resistant epilepsy | 5 mg/kg/day CBD m, titrated up to 50 mg/kg/day | Reduction in seizure frequency and severity | [ |
| Human | Dravet syndrome n | 100 mg/mL CBD o, oral solution at 2–10 mg/kg/day, titrated up to 25–50 mg/kg/day. Evaluating seizures at 12-week intervals through 96 weeks | Decrease in motor seizures and improved patients conditions | [ |
a Osteoarthritis causes joint degeneration, which is found both in humans and animals. Non-steroidal anti-inflammatory drugs (NSAIDs) and opioids are used for alleviating pain [81]. b Final desiccated CBD reconstituted into an olive oil base. c Delivered on food. d Solubilized in coconut oil. e With a sunflower lecithin base, each liposome encapsulated 10 to 20 mg/mL CBD. f Rheumatoid arthritis is an autoimmune and inflammatory disease that affects synovial tissue and generates joint inflammation and hyperplasia [104]. g Dissolved in ethanol, gel containing 1 or 10% CBD rubbed into the skin. h Prepared in a vehicle of ethanol/Tween 80/0.9% saline (3:1:16), injected intravenously (I.V.). i Neuropathic pain is a chronic pain caused by damage to a nerve or some diseases (e.g., type 1 diabetes and MS) that affects the somatosensory nervous system and is difficult to alleviate [81]. j Dissolved into 95% EtOH to a concentration of 20 mg/mL, then added to obtain a final concentration of 1 mg/15 mL (g) of gelatin. k CBD ≥99% purity, intraperitoneal injection (I.P.). l Dissolved with a 1:1:18 ratio of anhydrous ethanol, cremophor, and 0.9% saline. m Highly purified CBD in sesame oil (100 mg/mL; Epidiolex®) orally. n Dravet syndrome is drug-resistant epilepsy that starts during the first year of life [81]. o Highly purified CBD (100 mg/mL), oral solution (Epidiolex®). p 100 mg CBD/mL.
The effects of using hemp on liver function in poultry.
| Species | Experiment Duration | Hemp Type and Amount | Results | Reference |
|---|---|---|---|---|
| 19-week-old Bovan | 12 weeks | HS a: 10, 20% HSO b: 4, 8, 12% | Significant decrease in the expression of hepatic fatty acid desaturase | [ |
| 19-week-old Lohmann LSL- Classic | 12 weeks | HS: 10, 20, 30% | No significant effects on proteins, glucose, uric acid, and cholesterol plasma levels | [ |
| 1-day-old male Ross 308 | 35 days | EF d: 6% | HS + EF (5 and 6%): Positive increase in the vitamin E level in the liver | [ |
| 1-day-old Caribro-Vishal | 42 days | HS: 0.2% | Significant reduction in triglyceride, LDL g and total cholesterol levels, | [ |
a Hempseed, b hempseed oil, c aspartate transaminase, d extruded flaxseed, e dill seed, f bacitracin methylene disalicylate, g low-density lipoprotein, and h alanine transaminase.
CBD use effects on liver function in pets and mice.
| Species | Health Status | CBD Amount and Duration | Results | Reference |
|---|---|---|---|---|
| Dogs | OA pain and lameness | CBD oil: 2, 8 mg/kg | A significant increase in serum ALP a | [ |
| Dogs | Idiopathic epilepsy | CBD-infused oil: 2.5 mg/kg twice daily | A significant increase | [ |
| Dogs | Healthy | CBD chews: 2 mg/kg orally twice daily | No significant changes in serum chemistry | [ |
| 8-week-old mice | Healthy | CBD extract: | 2460 mg/kg: A significant increase in LBW b, plasma ALT c, AST d, and total bilirubin, | [ |
a Alkaline phosphatase, b liver-to-body weight, c alanine aminotransferase, and d aspartate transaminase.
Study results on hemp use in laying hens.
| Laying Hens | Experiment Duration | Hemp Type and Amount | Results | Reference |
|---|---|---|---|---|
| 19-week-old Lohmann | 6 weeks | HO a or HΩ b: 4 or 8% | Significant increase in total n-3 PUFAs c and a significant reduction in MUFAs d (both in egg yolks) in all groups | [ |
| 19-week-old Bovan white | 12 weeks | HO: 4, 8, 12% | 20% HS: Significantly increased egg weight | [ |
| 30-week-old Bovan white | 19 weeks | HSC f: 10, 20, 30% | Significant reduction in body weight in all treatments | [ |
| 30-week-old Bovan white | 3-week acclimation phase + | HSC: 10, 20, 30% | Significant increase in egg | [ |
| Lohmann Brown | 12 weeks | HS: 3, 6, 9% | 3% HS: Significantly increased egg production and mass | [ |
a Hemp oil, b hemp omega, c polyunsaturated fatty acids, d monounsaturated fatty acids, e hempseed, f hempseed cake, and g calcium.
The impact of Cannabis use on broilers.
| Broilers | Experiment Duration | Hemp Type and Amount | Results | Reference |
|---|---|---|---|---|
| 1-day-old male Ross 308 | From days 9 to 35 | HE a: 15 g/kg (12% CBD) | Upregulation in gene expression involved in gut barrier function | [ |
| 150-day-old mixed-sex Ross 308 | 21 days | HO or HΩ: 3 or 6% | Significant increase in total n-3 PUFAs in thighs and breasts | [ |
| 1-day-old male Ross 308 | 35 days | EF b: 6% | HS + EF (4% and 6%): Significantly increased body weight, decreased n-6/n-3 fatty acid ratio in breast meat | [ |
| 1-day-old male Ross 308 | 6 weeks | HS: 2.5, 5, 7.5% | HS 2.5%: Significant reduction in average daily feed intake and ADG d | [ |
| 1-day-old Caribro-Vishal | 42 days | HS: 0.2%, | Significant reduction in Coliform count in caecum and jejunum | [ |
a Hemp extract, b extruded flaxseed, c dextran oligosaccharide, d average daily gain, e dill seed, and f bacitracin methylene disalicylate.
The effect of hemp use on different animal species.
| Other Species | Experiment Duration | Hemp Type and Amount | Results | Reference |
|---|---|---|---|---|
| 7-day-old Japanese quails | 5 weeks | HS: 5%, 10%, 20% | 20% HS: Significant decrease in breast meat cooking loss | [ |
| 8-week-old laying quails | 6 weeks | HS: 5%, 10%, 20% | Significant linear increase in egg linoleic and linolenic FAs | [ |
| Swedish red | 5 weeks, 1 week (pre-experimental period) | HSC: 14.3, | 14.3% HSC: Higher milk yield | [ |
| Steers | 166 days | Full-fat HS: 9 or 14% | Significant increase in CLA a level, also trans and saturated fats in tissues | [ |
| Male Holstein cattle | 14 days | IH c: 25 g mixed in 200 g of grain (target daily dose of 5.5 mg/kg CBDA d) | Significant increase in lying behavior | [ |
| Male Holstein calves | Single oral dose, | IH: 35 g (target dose of 5.4 mg/kg CBDA) | No significant changes in serum parameters | [ |
| Carpathian goats | 31 days | HSO f: 93 g/day | Higher milk fat content, increase in conjugated fatty acid and PUFAs | [ |
| Pregnant sows | 10 days (before farrowing), 21 days (lactation period) | HS: 2% (10 days) | Significant improvement in sows oxidative status during lactation | [ |
a Conjugated linoleic acid, b dry matter intake, c industrial hemp (Cannabis sativa), d cannabidiolic acid, e prostaglandin E2, f hempseed oil, g total antioxidant capacity, and h nitric oxide production.